A recent case of “welder’s anthrax” in an 18-year-old apprentice from Louisiana has brought attention to a rare but serious occupational infection. Health authorities confirmed the case in September 2024, and it was later detailed in a 2026 report by the Centers for Disease Control and Prevention (CDC).1 This marks only the ninth documented case globally.
Welder’s anthrax is a severe lung infection that resembles inhalational anthrax but is caused by bacteria from the Bacillus cereus group, particularly strains that produce anthrax toxins. Unlike classical anthrax caused by Bacillus anthracis, this condition occurs primarily in individuals exposed to metalworking environments.
The teenager initially experienced cough and general illness, which progressed rapidly to severe pneumonia and respiratory failure within a few days. The condition required intensive care support, including mechanical ventilation. Such rapid progression highlights the severity of toxin-producing bacterial infections affecting the lungs.
The infection was identified in Louisiana, a region where all previously reported cases of welder’s anthrax have occurred. The illness was recognized in 2024 and formally documented in 2026. Most cases have been reported among welders and metalworkers in the southern United States.
Available data show that all known cases have involved individuals working in welding or metal-related occupations. These jobs often involve exposure to metal fumes and industrial dust. Among the nine reported cases, six have resulted in death, indicating a high fatality rate when diagnosis or treatment is delayed.1
The exact mechanism is still under investigation. However, research suggests that prolonged exposure to welding fumes may weaken the lungs’ natural defense systems. Environmental testing at the patient’s workplace detected anthrax toxin genes in a portion of collected samples, suggesting that contaminated dust or surfaces may serve as a source of exposure.
Despite similar exposure, no other workers at the site developed illness, indicating that individual susceptibility and additional risk factors may play a role.
Clinicians suspected welder’s anthrax based on occupational history, geographic location, and the severity of respiratory symptoms. Laboratory analysis confirmed the presence of toxin-producing Bacillus cereus group bacteria.
The patient received a combination of antibiotics along with anthrax antitoxin therapy (obiltoxaximab), administered in coordination with public health authorities. Early intervention led to clinical improvement, and the patient was discharged after 26 days. Follow-up at three months showed full recovery.
Early identification of rare infections like welder’s anthrax can significantly improve outcomes.
Health agencies recommend preventive measures such as improving workplace ventilation, minimizing exposure to metal fumes and dust, and using appropriate personal protective equipment. Awareness among clinicians and workers remains critical to reducing risk and ensuring timely treatment.
References
1. Thompson, Julie M., Eric W. Lundstrom, Lindsay D. Hein, et al. 2026. “Welder’s Anthrax Treated with Obiltoxaximab — Louisiana, 2024.” MMWR Morbidity and Mortality Weekly Report 74 (42): 641–647. https://doi.org/10.15585/mmwr.mm7442a1
(Rh/SS)
